This is a routine medical conference update with no material new data or regulatory catalyst. Monitor for any subsequent peer-reviewed publications or label expansion announcements, but no immediate trading action warranted.
Price Chart
Executive Summary
Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific Meeting, including post-hoc efficacy analyses and a network meta-analysis comparing SYMBRAVO to gepants for acute migraine treatment. This is a routine scientific conference update with no new regulatory or financial catalysts.
Key Facts
- Presentations at AHS 68th Annual Scientific Meeting, June 4-7 in Orlando, FL
- Four SYMBRAVO data presentations: post-hoc composite efficacy, network meta-analysis vs. gepants, sustained pain relief analysis, and safety endpoint analysis
- No new clinical trial results, regulatory decisions, or financial guidance provided
- SYMBRAVO is already FDA-approved for acute treatment of migraine
Financial Impact
No financial figures disclosed; routine scientific conference update
Risk Factors
- No new efficacy or safety signals disclosed that could change competitive positioning
- Network meta-analysis vs. gepants may not be considered definitive by prescribers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306621 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Institutional Cluster | $214.66 $211.12 | ▼ −1.65% | ▲ +0.25% | $176.28 (−17.88%) |
Aug 10, 2026 7w ago | 8-K | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.28 (−20.20%) |
Aug 10, 2026 7w ago | Press Release | $220.89 $207.82 | ▼ −5.92% | ▼ −5.00% | $176.28 (−20.20%) |
Jul 15, 2026 11w ago | Press Release | $237.53 $214.66 | ▼ −9.63% | ▼ −11.97% | $176.28 (−25.79%) |
Jul 9, 2026 12w ago | Court Ruling | $248.95 $210.13 | ▼ −15.59% | ▼ −17.84% | $176.28 (−29.19%) |
Jul 7, 2026 12w ago | Press Release | $249.76 $211.04 | ▼ −15.50% | ▼ −16.84% | $176.28 (−29.42%) |
Jul 1, 2026 13w ago | 144 | $244.31 $234.64 | ▼ −3.96% | ▼ −3.54% | $176.28 (−27.85%) |
Jun 15, 2026 15w ago | Press Release | $253.40 $228.28 | ▼ −9.91% | ▼ −9.16% | $176.28 (−30.43%) |
Jun 12, 2026 16w ago | Insider Cluster | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.28 (−30.92%) |
Jun 11, 2026 16w ago | 144 | $255.17 $233.80 | ▼ −8.37% | ▼ −10.15% | $176.28 (−30.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access